The African American Study of Kidney Disease and Hypertension (AASK) trial: What more have we learned?

Journal of Clinical Hypertension

Volumn 5, Issue 2, 2003, Pages 159-167

  Sica, Domenic A ^a  

^a VIRGINIA COMMONWEALTH UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMLODIPINE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIHYDROPYRIDINE DERIVATIVE; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; METOPROLOL; POTASSIUM; RAMIPRIL;

ADULT; AFRICA; ANGIONEUROTIC EDEMA; ARTICLE; BLOOD PRESSURE REGULATION; CARDIOVASCULAR RISK; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COUGHING; DEATH; DISEASE COURSE; DRUG USE; FEMALE; GLOMERULUS FILTRATION RATE; HUMAN; HYPERKALEMIA; HYPERTENSION; KIDNEY DISEASE; KIDNEY FAILURE; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NEPHROSCLEROSIS; POPULATION RESEARCH; RANDOMIZED CONTROLLED TRIAL; RISK BENEFIT ANALYSIS; RISK MANAGEMENT; TREATMENT OUTCOME; UNITED STATES;

EID: 0037368280     PISSN: 15246175     EISSN: None     Source Type: Journal    
DOI: 10.1111/j.1524-6175.2003.01924.x     Document Type: Article

References (26)

1. US Renal Data System. USRDS 2001 annual data report. Am J Kidney Dis. 2001;38(suppl 3):S37-S53.
2. Klag MJ, Whelton PK, Randall BL, et al. End-stage renal disease in African-American and white men. 16-year MRFIT findings. JAMA. 1997;277:1293-1298.
3. Sica DA, Douglas JG. The African American Study of Kidney Disease and Hypertension (AASK): new findings. J Clin Hypertens (Greenwich): 2001;3:244-251.
4. Freedman BI, Iskandar SS, Appel RG. In-depth review: the link between hypertension and nephrosclerosis. Am J Kidney Dis. 1995;25:207-221.
5. Lackland DT, Bendall HE, Osmond C, et al. Low birth weights contribute to high rates of early-onset chronic renal failure In the southeastern United States. Arch Intern Med. 2000;160:1472-1476.
6. Kinchen KS, Sadler J, Fink N, et al. The timing of specialist evaluation in chronic kidney disease and mortality. Ann Intern Med. 2002;137:479-486.
7. Wright JT Jr, Kuzek JW, Toto RD, et al. Design and baseline characteristics in African American Study of Kidney Disease and Hypertension (AASK) Pilot Study. Control Clin Trials. 1996;17(suppl 4):3S-16S.
8. Hall WD, Kusek JW, Kirk KA, et al. Short-term effects of blood pressure and antihypertensive drug regimen on glomerular filtration rate: the African-American Study of Kidney Disease and Hypertension Pilot Study. Am J Kidney Dis. 1997;29:720-728.
9. Agodoa LY, Appel L, Bakris G, et al. for the African American Study of Kidney Disease and Hypertension (AASK) Study Group. Effect of ramipril vs. amlodipine on renal outcomes in hypertensive nephrosclerosis. a randomized controlled trial. JAMA. 2001;285:2719-2728.
10. Bakris GL, Weir MR. Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern? Arch Intern Med. 2000;160:685-693.
11. Ruggenenti P, Gaspari F, Perna A, et al. Cross sectional longitudinal study of spot morning urine protein: creatinine ratio, 24 hour urine protein excretion rate, glomerular filtration rare, and end stage renal failure in chronic renal disease in patients without diabetes. BMJ. 1998;316:504-509.
12. Giatras I, Lau J, Levey AS. for the Angiotensin-Converting-Enzyme Inhibition and Progressive Renal Disease Study Group, Effect of angiotensin-converting enzyme inhibitors on the progression of nondiabetic renal disease: a meta-analysis of randomized trials. Ann Intern Med. 1997;127:337-345.
13. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic renal insufficiency. N Engl J Med. 1996;334:939-945.
14. Lewis EJ, Hunsicker LG, Bain RP, et, al. The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group. N Engl J Med. 1993;329:1456-1462.
15. Ruggenenti P, Perna A, Gherardi G, et al. Renal function and requirement for dialysis in chronic nephropathy patients on long-term ramipril: REIN follow-up trial. Gruppo Italiano, di Studi Epidemiologici in Nefrologia (GISEN). Ramipril Efficacy In Nephropathy. Lancet. 1998;352:1252-1256.
16. Klahr S, Levey AS, Beck GJ, et al. Blood pressure control, proteinuria, and the progression of renal disease. The Modification of Diet in Renal Disease Study. Ann Intern Med. 1995;123:754-762.
17. Rodby RA, Rohde RD, Clarke WR, et al. The irbesartan type II diabetic nephropathy trial: study design and baseline patient characteristics. For the Collaborative Study Group. Nephrol Dial Transplant. 2000;15:487-497.
18. Brenner BM, Cooper ME, de Zeeuw D, et al. The losartan renal protection study-rationale, study design and baseline characteristics of RENAAL (Reduction of Endpoints in NIDDM with the Angiotensin II Antagonist Losartan). J Renin Angiotensin Aldosterone Sys. 2000;1:328-335.
19. Wright JT Jr, Bakris G, Greene T, et al. Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney disease: results from the AASK trial. JAMA. 2002;288:2421-2431.
20. Wright JT Jr, Agodoa L, Contreras G, et al. Successful blood pressure control in the African American Study of Kidney Disease and Hypertension. Arch Intern Med. 2002;162:1636-1643.
21. Sica DA, Black HR. Current concepts of pharmacotherapy in hypertension: ACE inhibitor-related angioedema: can angiotensin-receptor blockers be safely used? J Clin Hypertens (Greenwich). 2002;4:375-380.
22. Schoolwerth AC, Sica DA, Ballermann BJ, et al. Renal considerations in angiotensin converting enzyme inhibitor therapy: a statement for healthcare professionals from the Council on the Kidney in Cardiovascular Disease and the Council for High Blood Pressure Research of the American Heart Association. Circulation. 2001;104.1985-1991.
23. Sica DA. Kinetics of angiotensin-converting enzyme inhibitors in renal failure. J Cardiovasc Pharmacol. 1992; 20(suppl. 10):S13-S20.
24. Sica DA, Cutler RE, Parmer RJ, et al. Comparison of the steady-state pharmacokinetics of fosinopril, lisinopril and enalapril in patients with chronic renal insufficiency. Clin Pharmacokinet. 1991;20:420-427.
25. Kloke HJ, Branten AJ, Huysmans FT, et al. Antihypertensive treatment of patients with proteinuric renal diseases: risks or benefits of calcium channel blockers? Kidney Int. 1998;53:1559-1573.
26. Bakris GL, Weir MR, DeQuattro V, et al. Effects of an ACE inhibitor/calcium antagonist combination on proteinuria in diabetic nephropathy. Kidney Int. 1998;54:1283-1289.